Intra-Cellular approval keeps focus on FDA's neuroscience review process

The Food and Drug Administration on Monday approved Intra-Cellular's lumateperone as a treatment for adults with schizophrenia, a decision that supports speculation the agency is taking a more flexible approach when evaluating neuroscience medicines. Lumateperone, which will be sold as Caplyta, showed conflicting results in late-stage testing.